Merck KGaA’s CFO on Sales Growth, Asia, Life Sciences, Semiconductor Additions

The video discusses Merck's sales growth, particularly in Asia and the life sciences sector, highlighting strong market dynamics driven by demand for monoclonal antibodies and biologics. It covers the impact of recent semiconductor acquisitions on performance materials, aiming to reduce reliance on liquid crystals. The healthcare segment addresses the decline of Rebif and the potential of newly approved products like Mavenclad to compensate for this decline.

In what ways does the company believe semiconductor growth will affect its future?

How does the company plan to address the decline in Rebif sales?

What are the expected peak sales potential figures for the newly approved product?